1 Name of the Medicinal Product
Colgate Periogard 0.2% Oromucosal Solution
2 Qualitative and Quantitative Composition
1ml contains 2mg chlorhexidine digluconate. One dose of 10ml contains 20mg chlorhexidine digluconate.
Excipient: Macrogolglycerol hydroxystearate 2.5mg/ml
For a full list of excipients, see section 6.1
3 Pharmaceutical Form
Oromucosal solution. Clear blue solution
4.1 Therapeutic indications
Colgate Periogard 0.2 % Oromucosal Solution is indicated in adults and children above the age of 6
- for the short-term adjuvant treatment of inflammations of the gingival and the oral mucosa.
- for pre- and post-procedural use in periodontal therapies to prevent infections of oral surgical wounds.
4.2 Posology and method of administration
For adults and children above the age of 6:
The oral cavity should be rinsed thoroughly with 10 ml Colgate Periogard 0.2 % Oromucosal Solution twice a day for one minute and spit out afterwards. The solution should be applied after teeth have been brushed and the oral cavity rinsed thoroughly with water. The solution is ready for use and should hence be used undiluted.
Colgate Periogard 0.2 % Oromucosal Solution would normally not be used for more than 7 days at a time. It may be used over a longer period of time if advised by the dentist or the physician.
Children above the age of 6 and the elderly:
There are no special dosage recommendations for either elderly patients or children above the age of 6. The normal adult dose is appropriate unless otherwise recommended by the dentist or the physician.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients.
The use of a mouth rinse is contraindicated in conditions where it is presumed that the oromucosal solution may be swallowed.
4.4 Special warnings and precautions for use
For oromucosal use only - should be kept out of the eyes and ears, or other tissues except the oral mucosa. If the mouthwash comes into contact with the eyes, it should be washed out promptly and thoroughly with plenty of water.
In the case of ulcerations and erosive-desquamative exfoliation of the oral mucosa, the medicinal product should not be used.
Continuous use of Colgate Periogard 0.2 % Oromucosal Solution as an oral rinsing solution without mechanically cleaning the teeth may enhance gingival bleeding.
Continuous use could modify the oral microbial flora, this being associated with the risk of bacterial and fungal spreading (candidiasis). If symptoms persist after 7 days and/or are associated with fever, therapeutic options should be reconsidered.
Chlorhexidine digluconate may cause acute allergic reactions including anaphylaxis (see section 4.8).
Sugar-containing food or drinks should not be consumed within an hour of using Colgate Periogard 0.2 % Oromucosal Solution.
Macrogolglycerol hydroxystearate may cause skin reactions.
4.5 Interaction with other medicinal products and other forms of interaction
The efficacy of chlorhexidine is influenced by anionic substances (e.g. sodium dodecyl sulphate, synonym: sodium lauryl sulphate), which may be components of toothpastes. Therefore, these should not be used simultaneously with Colgate Periogard 0.2 % Oromucosal Solution but before the oral cavity is rinsed with chlorhexidine (see section 4.2). This restriction does not apply to toothpastes containing amphoteric tensides.
Colgate Periogard 0.2 % Oromucosal Solution can cause stains when spilt on clothing.
4.6 Pregnancy and lactation
Pregnancy
Colgate Periogard 0.2 % Oromucosal Solution should be used with caution in pregnancy, since there is not enough clinical experience with chlorhexidine in pregnant women.
Lactation
It is not documented whether or not chlorhexidine is excreted in human milk, therefore caution should be exercised when administering the medicinal product to nursing women.
4.7 Effects on ability to drive and use machines
No studies on the effects of the ability to drive and use machines have been performed. No effect is expected.
4.8 Undesirable effects
Very common (≥ 1/10)
Common (≥ 1/100, < 1/10)
Uncommon (≥ 1/1,000, < 1/100)
Rare (≥ 1/10,000, < 1/1,000)
Very rare (< 1/10,000), not known (cannot be estimated from the available data)
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Eye disorders
Very rare: Corneal lesion following accidental application to the eye.
Gastrointestinal disorders
Very common: Tongue discolouration and teeth staining. These discolourations of hard tooth substance and dental restorations can be removed by the dentist in most cases but a professional prophylaxis may be required in some cases.
Taste alteration, oral paraesthesia, tongue irritation and/or oral mucosal irritation (stomatitis). These effects are reversible after finishing the application of Colgate Periogard solution.
Common: Dental calculus, oral mucosal exfoliation and stomatitis.
Uncommon: Oral mucosal disorder.
Very rare: Reversible parotid swelling.
Skin and subcutaneous tissue disorders
Rare: Rash.
Immune systems disorders
Rare: Anaphylactic reactions with symptoms such as bronchospasm, dyspnea, peri-orbital oedema, hypotension, and shock, allergic reactions after local application of chlorhexidine, hypersensitivity reactions.
4.9 Overdose
Signs of intoxication are not known. Chlorhexidine swallowed accidentally is poorly absorbed by the digestive system.
5 Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Anti-infective and antiseptics for local oral treatment.
ATC-Code: A01AB03.
Chlorhexidine is a base and therefore most stable in the form of a salt. The free base, the diacetate and the dihydrochloride are only poorly soluble in water whereas the digluconate (Synonym: bis (D-gluconate)) (> 50g/100 ml) is very soluble in water. Hence, the digluconate is used.
Chlorhexidine and its salts show a broad antimicrobial effect against gram-positive and gram-negative bacteria.
The effect against some gram-negative bacteria (Pseudomonas- and Proteus-types) and against certain yeasts, dermatophytes and mycobacteria is poor. It is ineffective against bacteria spores and fungus spores, viruses and putrefactive fungi. In the presence of soaps, blood and pus (fractions of cells) the efficacy of chlorhexidine is reduced. Rinsing the mouth with 10 ml of a 0.2 % chlorhexidine-solution leads to a strong reduction of the quantity of bacteria in saliva. This correlates with a reduced rate of formation of dental plaque. When using the oromucosal solution over several months the efficacy decreases by the reversible shift in the bacteria spectrum of oral flora and tooth plaque.
The antibacterial properties of chlorhexidine are on the one hand directed against acid producing, cariogenic microorganisms of the dental plaque and on the other hand also against anaerobic and facultatively anaerobic microorganisms which lead to inflammations of the gingiva. Thus, chlorhexidine prevents inflammation of the gingiva caused by bacteria.
5.2 Pharmacokinetic properties
After repeated application of chlorhexidine on healthy skin no absorption of the substance could be seen in adults. In contrast, small amounts of the substance (up to 1.0 µg/ml) were found in the blood of preterm and newborn infants (28th to 39th week of pregnancy) after bathing them in 4 % chlorhexidine digluconate-detergent solution (no clinical symptoms).
Due to its cationic character chlorhexidine fixes strongly to the skin, mucosa and other tissues and is thus poorly absorbed.
After rinsing the mouth, chlorhexidine adsorbs to the dental enamel, dentine, cement, dental pellicles, mucosa and dental restorations. Due to slow adsorption, chlorhexidine is detectable in the saliva up to eight hours (depot effect). The absorption of chlorhexidine via intact oral mucosa is not known.
In different test species, chlorhexidine is excreted via the faeces (90 %) and only approximately 1 % via the urine. In humans, the elimination half-life was 4 days.
5.3 Preclinical safety data
Non-clinical data reveal no special hazard for humans based on studies of repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction.
6 Pharmaceutical Particulars
6.1 List of excipients
Sorbitol, liquid (non-crystallising), glycerol, macrogol glycerol hydroxystearate, citric acid monohydrate (for pH-adjustment), peppermint oil, patent blue V (E 131), purified water
6.2 Incompatibilities
Chlorhexidine is incompatible with anionic substances that may be components of toothpastes. Chlorhexidine is inactivated by sucrose.
6.3 Shelf life
3 years
After first opening the medicinal product should not be used longer than 4 weeks.
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.
6.5 Nature and contents of container
Bottle made of polyethylene terephthalate with a screw cap and a sealing ring made of polyethylene. The measuring device of 10 ml made of polypropylene is part of the screw cap.
The bottle contains 300 ml solution.
6.6 Special precautions for disposal
Any unused product or waste material should be disposed of in accordance with local requirements.
7 Marketing Authorisation Holder
GABA GmbH
Berner Weg 7
D-79539 Lörrach
Germany
Tel: 0049 7621 907 0
Fax: 0049 7621 907 499
E-Mail: info@gaba-dent.de
8 Marketing Authorisation Number(s)
PL 31347/0001
9 Date of Revision of the Text
February 2008
10 Legal Classification
GSL
12 Manufacturer's Recommended Retail Price
£3.89 (300ml bottle)